A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: A Children's Oncology Group Phase I Consortium Report

Authors

Brigitte C. Widemann, National Cancer Institute, Bethesda, MD
AeRang Kim, George Washington University
Elizabeth Fox, Children's Hospital Philadelphia
Sylvain Baruchel, Hospital for Sick Children, Toronto, ON
Peter C. Adamson, Children's Hospital PhiladelphiaFollow
Ashish M. Ingle, Children's Oncology Group, Arcadia, CA
Julia G. Bender, Columbia University
Michael Burke, University of Minnesota
Brenda Weigel, University of MinnesotaFollow
Diana Stempak, Hospital for Sick Children, Toronto, ON
Frank M. Balis, Children's Hospital Philadelphia
Susan M. Blaney, Texas Children's Cancer Center, Houston, TX

Document Type

Journal Article

Publication Date

11-2012

Journal

Clinical Cancer Research

Volume

Volume 18, Issue 21

Inclusive Pages

6011-6022

Keywords

Antineoplastic Agents--therapeutic use; Leukemia--drug therapy; Neoplasms--drug therapy; Niacinamide--analogs & derivatives; Phenylurea Compounds--therapeutic use; Protein Kinase Inhibitors--therapeutic use

APA Citation

Widemann, B.C., Kim, A., Fox, E., Baruchel, S., Adamson, P.C., Ingle, A.M., Bender, J., Burke, M., Weigel, B., Stempak, D., Balis, F.M., Blaney, S.M. (2012). A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clinical Cancer Research, 18(21), 6011-6022.

Peer Reviewed

1